NR3C1

(redirected from GCCR)
Also found in: Acronyms.

NR3C1

A gene on chromosome 5q31.3 that encodes a glucocorticoid receptor, which acts as either a transcription factor that binds to glucocorticoid response elements in the promoters of glucocorticoid responsive genes to activate their transcription, or as a regulator of other transcription factors.

Molecular pathology
NR3C1 mutation are associated with generalised glucocorticoid resistance.
References in periodicals archive ?
In this study, each treatment type was analyzed separately because determining the optimal proportion of patients who should receive a particular BC treatment modality according to clinical indicators using the GCCR data is not possible.
As a result, the most significant limitation was limiting the analysis to all-cause mortality instead of using cause-specific survival analysis because the GCCR does not collect information on cause of death, which makes it difficult to rule out deaths due to other confounding individual and contextual factors.
Finally, although cancer registry data (Zippin, Lum, and Hankey 1995) including the GCCR have high completeness for incident cases (Clarkson 2007), research has shown that the quality and completeness of treatment data need improvement (Malin et al.
The GCCR includes the Surveillance, Epidemiology, and End Results (SEER) Program summary stage, which can be used for all types of cancer.
The decision of whether we kept the stage data as found in the GCCR or changed it using claims was based on whether the woman enrolled in Medicaid within six months of her cancer diagnosis.
Isis purchased Symphony GenIsis relatively early in the term of that financing arrangement saving approximately $75 million in the predetermined purchase price, regaining full ownership of mipomersen, which Isis licensed to Genzyme, and the GCGR and GCCR drugs, which Isis licensed to OMI.
Although inhibition of GCCR has long been recognized as an attractive strategy for development of therapeutics for Type 2 diabetes, the side effects associated with systemic GCCR inhibition have challenged development of traditional drugs.
Financing and Other Corporate Activity * In 2006, Isis received $75 million from its collaboration with Symphony Capital to fund continued development of ISIS 301012 and two preclinical metabolic program drugs targeting GCGR and GCCR.
GCs work by binding to GCCR; as a result, reducing GCCR levels should attenuate GC action and have a positive effect on glucose control.
Isis has studied its second-generation ASOs targeting GCCR in multiple animal models.